Total Payments
$3,731
2024 Payments
$1,127
Companies
45
Transactions
143
Medicare Patients
3,564
Medicare Billing
$597,909
Payment Breakdown by Category
Food & Beverage$2,460 (65.9%)
Education$1,271 (34.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $2,460 | 122 | 65.9% |
| Education | $1,271 | 21 | 34.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Astellas Pharma US Inc | $491.15 | 12 | $0 (2024) |
| SANOFI-AVENTIS U.S. LLC | $326.93 | 4 | $0 (2023) |
| Novartis Pharmaceuticals Corporation | $314.81 | 16 | $0 (2024) |
| Amgen Inc. | $308.78 | 14 | $0 (2023) |
| AVEO Pharmaceuticals, Inc. | $157.21 | 5 | $0 (2023) |
| Seagen Inc. | $157.10 | 5 | $0 (2023) |
| Daiichi Sankyo Inc. | $141.38 | 4 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $139.63 | 6 | $0 (2024) |
| PFIZER INC. | $139.39 | 7 | $0 (2024) |
| Eisai Inc. | $117.72 | 6 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,127 | 43 | Astellas Pharma US Inc ($140.40) |
| 2023 | $835.96 | 34 | Astellas Pharma US Inc ($139.36) |
| 2022 | $958.49 | 34 | Astellas Pharma US Inc ($151.40) |
| 2021 | $275.74 | 15 | Amgen Inc. ($61.65) |
| 2020 | $59.99 | 1 | Astellas Pharma US Inc ($59.99) |
| 2019 | $112.99 | 2 | SANOFI-AVENTIS U.S. LLC ($99.95) |
| 2018 | $194.82 | 7 | Amgen Inc. ($105.03) |
| 2017 | $166.01 | 7 | SANOFI-AVENTIS U.S. LLC ($74.99) |
All Payment Transactions
143 individual payment records from CMS Open Payments — Page 1 of 6
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/11/2024 | Novartis Pharmaceuticals Corporation | SCEMBLIX (Drug) | Food and Beverage | In-kind items and services | $20.50 | General |
| Category: Oncology | ||||||
| 12/04/2024 | BeiGene USA, Inc. | TEVIMBRA (Drug) | Food and Beverage | In-kind items and services | $22.97 | General |
| Category: Oncology | ||||||
| 11/20/2024 | Exelixis Inc. | CABOMETYX (Drug) | Food and Beverage | In-kind items and services | $24.12 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 11/14/2024 | Acrotech Biopharma Inc. | BELEODAQ (Drug) | Food and Beverage | In-kind items and services | $25.24 | General |
| Category: ONCOLOGY | ||||||
| 11/13/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $16.64 | General |
| 10/30/2024 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $24.70 | General |
| 10/24/2024 | Novartis Pharmaceuticals Corporation | PLUVICTO (Drug) | Food and Beverage | In-kind items and services | $18.13 | General |
| Category: Oncology | ||||||
| 10/24/2024 | Novartis Pharmaceuticals Corporation | PLUVICTO (Drug) | Food and Beverage | In-kind items and services | $3.15 | General |
| Category: Oncology | ||||||
| 10/17/2024 | Blueprint Medicines Corporation | AYVAKIT (Drug) | Food and Beverage | Cash or cash equivalent | $20.78 | General |
| Category: Oncology / Rare Diseases | ||||||
| 10/15/2024 | Genentech USA, Inc. | Itovebi (Biological), Phesgo | Food and Beverage | In-kind items and services | $27.35 | General |
| Category: BioOncology | ||||||
| 10/10/2024 | PFIZER INC. | IBRANCE (Drug), TUKYSA | Food and Beverage | In-kind items and services | $21.81 | General |
| Category: ONCOLOGY | ||||||
| 09/25/2024 | Novartis Pharmaceuticals Corporation | Fabhalta (Drug) | Food and Beverage | In-kind items and services | $33.81 | General |
| Category: Immunology | ||||||
| 09/05/2024 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $20.49 | General |
| Category: Hematology | ||||||
| 09/04/2024 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $20.95 | General |
| 08/28/2024 | AstraZeneca Pharmaceuticals LP | IMFINZI (Biological) | Food and Beverage | In-kind items and services | $27.99 | General |
| Category: Oncology | ||||||
| 08/22/2024 | Incyte Corporation | JAKAFI (Drug) | Food and Beverage | Cash or cash equivalent | $28.17 | General |
| Category: Hematology/Oncology | ||||||
| 08/09/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Education | In-kind items and services | $89.99 | General |
| Category: ONCOLOGY | ||||||
| 08/01/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $21.39 | General |
| Category: ONCOLOGY | ||||||
| 07/17/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $17.50 | General |
| 07/10/2024 | Astellas Pharma US Inc | — | Education | In-kind items and services | $99.00 | General |
| 06/27/2024 | Deciphera Pharmaceuticals Inc. | QINLOCK (Drug) | Food and Beverage | In-kind items and services | $17.13 | General |
| Category: ONCOLOGY | ||||||
| 06/14/2024 | Janssen Biotech, Inc. | DARZALEX (Biological) | Education | In-kind items and services | $99.00 | General |
| Category: Oncology | ||||||
| 06/06/2024 | RECORDATI_RARE_DISEASES_INC. | SYLVANT (Drug) | Food and Beverage | In-kind items and services | $23.89 | General |
| Category: ONCOLOGIC AGENT | ||||||
| 05/31/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $20.38 | General |
| 05/24/2024 | Boston Scientific Corporation | — | Food and Beverage | In-kind items and services | $14.56 | General |
| Category: General - Pain Management_NMD | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 20 | 909 | 4,442 | $731,817 | $186,313 |
| 2022 | 15 | 1,105 | 7,307 | $757,858 | $223,104 |
| 2021 | 12 | 836 | 1,303 | $397,584 | $104,670 |
| 2020 | 11 | 714 | 1,251 | $247,434 | $83,822 |
Total Patients
3,564
Total Services
14,303
Medicare Billing
$597,909
Procedure Codes
58
All Medicare Procedures & Services
58 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 328 | 888 | $333,888 | $84,235 | 25.2% |
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 14 | 2,280 | $163,020 | $41,540 | 25.5% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 16 | 155 | $68,665 | $15,861 | 23.1% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 62 | 62 | $40,176 | $10,903 | 27.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 130 | 155 | $41,075 | $10,480 | 25.5% |
| 99231 | Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | Facility | 2023 | 25 | 115 | $12,995 | $4,597 | 35.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 18 | 18 | $9,624 | $2,475 | 25.7% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 14 | 193 | $9,843 | $2,367 | 24.0% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 16 | 23 | $9,016 | $2,293 | 25.4% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 20 | 24 | $7,056 | $2,220 | 31.5% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 25 | 41 | $9,061 | $1,991 | 22.0% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 15 | 31 | $6,386 | $1,925 | 30.1% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Office | 2023 | 19 | 25 | $6,675 | $1,525 | 22.9% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 39 | 98 | $4,116 | $1,066 | 25.9% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 84 | 97 | $2,231 | $738.17 | 33.1% |
| J3489 | Injection, zoledronic acid, 1 mg | Office | 2023 | 21 | 126 | $3,134 | $717.43 | 22.9% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 14 | 15 | $2,490 | $637.00 | 25.6% |
| 99441 | Telephone medical discussion with physician, 5-10 minutes | Office | 2023 | 11 | 11 | $1,826 | $446.20 | 24.4% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 18 | 28 | $280.00 | $235.20 | 84.0% |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | Office | 2023 | 20 | 57 | $260.00 | $60.54 | 23.3% |
| J0897 | Injection, denosumab, 1 mg | Office | 2022 | 21 | 4,980 | $233,880 | $84,824 | 36.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 286 | 706 | $265,456 | $71,243 | 26.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 187 | 249 | $65,985 | $17,700 | 26.8% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2022 | 22 | 158 | $69,994 | $16,800 | 24.0% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 47 | 47 | $30,456 | $7,856 | 25.8% |
About Dr. Oscar Signori, MD
Dr. Oscar Signori, MD is a Hematology & Oncology healthcare provider based in Dearborn, Michigan. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 03/07/2006. The National Provider Identifier (NPI) number assigned to this provider is 1285601435.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Oscar Signori, MD has received a total of $3,731 in payments from pharmaceutical and medical device companies, with $1,127 received in 2024. These payments were reported across 143 transactions from 45 companies. The most common payment nature is "Food and Beverage" ($2,460).
As a Medicare-enrolled provider, Signori has provided services to 3,564 Medicare beneficiaries, totaling 14,303 services with total Medicare billing of $597,909. Data is available for 4 years (2020–2023), covering 58 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Dearborn, MI
- Active Since 03/07/2006
- Last Updated 01/29/2025
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1285601435
Products in Payments
- JEVTANA (Drug) $289.66
- FOTIVDA (Drug) $157.21
- Enhertu (Drug) $127.61
- Lenvima (Drug) $117.72
- IMFINZI (Biological) $114.77
- LUMAKRAS (Drug) $102.11
- DARZALEX (Biological) $99.00
- IBRANCE (Drug) $86.41
- PADCEV (Biological) $86.25
- SIR-Spheres Microspheres (Device) $78.73
- ZALTRAP (Drug) $74.99
- XPOVIO (Drug) $73.13
- Xtandi (Drug) $71.26
- SCEMBLIX (Drug) $67.09
- MEKINIST (Drug) $65.87
- SARCLISA (Biological) $57.82
- Nplate (Biological) $49.94
- BELEODAQ (Drug) $49.02
- Padcev (Drug) $48.89
- JAKAFI (Drug) $47.61
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Dearborn
Faisal Musa, Md, MD
Hematology & Oncology — Payments: $922,775
Hematology & Oncology $922,775
Dr. Mirna Farhat, Md, MD
Hematology & Oncology — Payments: $4,876
Hematology & Oncology $4,876
Dr. Feroze Momin, Md, MD
Hematology & Oncology — Payments: $276.49
Hematology & Oncology $276.49
Dr. Renu Pandit, M.d, M.D
Hematology & Oncology — Payments: $207.88
Hematology & Oncology $207.88